{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:30:00Z","timestamp":1790667000074,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00467-018-3900-z","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T08:49:26Z","timestamp":1518166166000},"page":"1013-1018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome"],"prefix":"10.1007","volume":"33","author":[{"given":"Koichi","family":"Kamei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"3900_CR1","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel WH (2010) Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 14:E10\u2013E21","journal-title":"Clin J Oncol Nurs"},{"key":"3900_CR2","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217\u20132224","journal-title":"Blood"},{"key":"3900_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/sj.thj.6200133","volume":"2","author":"J Bienvenu","year":"2001","unstructured":"Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B, Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (2001) Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2:378\u2013384","journal-title":"Hematol J"},{"key":"3900_CR4","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153\u20132164","journal-title":"J Clin Oncol"},{"key":"3900_CR5","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457\u20132466","journal-title":"Blood"},{"key":"3900_CR6","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol 15:3266\u20133274","journal-title":"J Clin Oncol"},{"key":"3900_CR7","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"3900_CR8","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"key":"3900_CR9","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","volume":"17","author":"TA Davis","year":"1999","unstructured":"Davis TA, White CA, Grillo-L\u00f3pez AJ, Vel\u00e1squez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 17:1851\u20131857","journal-title":"J Clin Oncol"},{"key":"3900_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/A:1008389119525","volume":"10","author":"LD Piro","year":"1999","unstructured":"Piro LD, White CA, Grillo-L\u00f3pez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10:655\u2013661","journal-title":"Ann Oncol"},{"key":"3900_CR11","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-L\u00f3pez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135\u20133143","journal-title":"J Clin Oncol"},{"key":"3900_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601\u2013609","journal-title":"Oncologist"},{"key":"3900_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00520-007-0329-5","volume":"16","author":"LS Schwartzberg","year":"2008","unstructured":"Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC (2008) Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 16:393\u2013398","journal-title":"Support Care Cancer"},{"key":"3900_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"issue":"6 Suppl 12","key":"3900_CR15","first-page":"53","volume":"27","author":"L Kunkel","year":"2000","unstructured":"Kunkel L, Wong A, Maneatis T, Nickas J, Brown T, Grillo-L\u00f3pez A, Benyunes M, Grobman B, Dillman RO (2000) Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. Semin Oncol 27(6 Suppl 12):53\u201361","journal-title":"Semin Oncol"},{"key":"3900_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725\u2013732","journal-title":"Oncologist"},{"key":"3900_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10157-014-1030-x","volume":"19","author":"K Ishikura","year":"2015","unstructured":"Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K, Japanese Society for Pediatric Nephrology (2015) Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol 19:6\u201333","journal-title":"Clin Exp Nephrol"},{"key":"3900_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281","journal-title":"Lancet"},{"key":"3900_CR19","first-page":"369","volume":"22","author":"C Legeay","year":"2017","unstructured":"Legeay C, Bittencourt H, Haddad E, Spiesser-Robelet L, Th\u00e9pot-Seegers V, Therrien R (2017) A retrospective study on infusion-related reactions to rituximab in a heterogeneous pediatric population. J Pediatr Pharmacol Ther 22:369\u2013374","journal-title":"J Pediatr Pharmacol Ther"},{"key":"3900_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/jmv.24042","volume":"87","author":"KM Henriquez","year":"2015","unstructured":"Henriquez KM, Hayney MS, Xie Y, Zhang Z, Barrett B (2015) Association of interleukin-8 and neutrophils with nasal symptom severity during acute respiratory infection. J Med Virol 87:330\u2013337","journal-title":"J Med Virol"},{"key":"3900_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1440-1843.2005.00721.x","volume":"10","author":"PM Pitrez","year":"2005","unstructured":"Pitrez PM, Brennan S, Sly PD (2005) Inflammatory profile in nasal secretions of infants hospitalized with acute lower airway tract infections. Respirology 10:365\u2013370","journal-title":"Respirology"},{"key":"3900_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ndt\/gfu258","volume":"30","author":"K Kamei","year":"2015","unstructured":"Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura M, Ito S (2015) Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant 30:91\u201396","journal-title":"Nephrol Dial Transplant"},{"key":"3900_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"28","author":"M Sato","year":"2013","unstructured":"Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28:145\u2013149","journal-title":"Pediatr Nephrol"},{"key":"3900_CR24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Desch\u00eanes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753\u20131755","journal-title":"Pediatr Nephrol"},{"key":"3900_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/resp.12214","volume":"19","author":"GJ Keir","year":"2014","unstructured":"Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353\u2013359","journal-title":"Respirology"},{"key":"3900_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2169\/internalmedicine.54.2308","volume":"54","author":"Y Sano","year":"2015","unstructured":"Sano Y, Nakano Y, Omoto M, Takao M, Ikeda E, Oga A, Nakamichi K, Saijo M, Maoka T, Sano H, Kawai M, Kanda T (2015) Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment. Intern Med 54:965\u2013970","journal-title":"Intern Med"},{"key":"3900_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.36290\/vnl.2017.012","volume":"63","author":"J Sokol","year":"2017","unstructured":"Sokol J, Lis\u00e1 L, Zele\u0148\u00e1kov\u00e1 J, Balh\u00e1rek T, Plame\u0148ov\u00e1 I, Sta\u0161ko J, Kubisz P (2017) Rituximab-associated progressive multifocal leukoencephalopathy. Vnitr Lek 63:60\u201364","journal-title":"Vnitr Lek"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-018-3900-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3900-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3900-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:22:35Z","timestamp":1659054155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-018-3900-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3900"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-3900-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"16 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KK has received lecture fees from the Chugai Pharmaceutical Co., Ltd. SI has received lecture fees and\/or grants from the Chugai Pharmaceutical Co., Ltd.; Zenyaku Kogyo Co., Ltd.; Asahi Kasei Pharma; Novartis Pharma K.K.; and Astellas Pharma Inc. KI has received lecture fees from the Asahi Kasei Pharma; Chugai Pharmaceutical Co., Ltd.; Zenyaku Kogyo Co., Ltd.; and Novartis Pharma K.K. and a consultant fee from Ono Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The design and execution of this study were in accordance with the ethical standards of the Declaration of Helsinki. The protocol was approved by the Ethics Committee of the National Center for Child Health and Development (no. 1505).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}